Alzheimer’s Drugs on Verge of Becoming Mainstream Medicine, but Early Intervention Still is Needed

Diagnostics and therapeutics for Alzheimer’s disease are on the verge of becoming mainstream medicine. It’s about time, too. This neurodegenerative disease is creating a crisis in healthcare, with a bill of $300 billion in direct costs and $250 billion in unpaid care provided by families.

Biogen’s submission of a biologics license application (BLA) for aducanumab Wednesday is the leading edge of what could be a tsunami of business opportunities.